High Rheumatoid Factor Solution (Purified) – Research Use Only

High Rheumatoid Factor Solution (Purified) is a biotechnology-grade interference testing reagent supplied as a 1 mL purified solution for applications involving immunoassay validation, interference studies, analytical robustness testing, and diagnostic assay development. This reagent contains purified rheumatoid factor (RF) in defined titer ranges, enabling researchers and assay developers to evaluate the impact of RF-related interference across a broad range of testing conditions. It is especially useful in workflows involving ELISA, CLIA, nephelometry, autoantibody testing, biomarker quantitation, and matrix effect evaluation.

Scientific Overview

Rheumatoid factor is a well-known source of analytical interference in immunoassay systems, particularly in workflows involving IgG-based binding formats, cytokine assays, autoantibody detection, and certain cardiac or inflammatory biomarker platforms. Because RF can bind assay components nonspecifically or alter signal generation, it is frequently used in validation workflows designed to assess assay specificity, robustness, and susceptibility to false-positive or distorted results.

This purified RF solution is especially useful for laboratories performing interference challenge studies, matrix spiking experiments, cross-reactivity evaluation, and assay troubleshooting. The availability of multiple defined RF titer ranges allows researchers to model varying levels of interference burden and better understand assay behavior across low, moderate, and very high RF conditions.

Applications

• Interference testing in immunoassay development and validation
• Matrix spiking and assay robustness studies
• Cross-reactivity and false-signal evaluation
• Validation of ELISA, CLIA, nephelometric, and related platforms
• Analytical troubleshooting for RF-sensitive workflows

Usage & Handling Guidance

Store at -20°C as specified. This reagent is supplied as a purified solution and may be used directly or diluted according to the intended validation or interference-testing protocol. Researchers should establish appropriate spike levels, matrix conditions, and assay acceptance criteria based on the specific analytical platform and intended performance claims.

• Preparation: Use directly or dilute into the intended serum, plasma, or assay matrix as required
• Handling: Minimize repeated freeze-thaw cycles where possible to support consistency
• Optimization: Select RF titer range based on the intended interference challenge design
• Workflow note: Validate assay response within the intended analytical system and matrix context

What You Get

• 1 mL purified rheumatoid factor solution
• Available in 8 defined RF titer ranges
• Suitable for assay validation and interference testing workflows
• Biotechnology-grade reagent for analytical development use
• For research use only (RUO)

Why Researchers Choose It

• Designed specifically for RF-related assay interference evaluation
• Multiple titer ranges support realistic validation and challenge studies
• Useful across ELISA, CLIA, nephelometric, and biomarker platforms
• Supports troubleshooting of false signal and matrix-related performance issues
• Convenient 1 mL purified solution format for lab workflows

Frequently Asked Questions (FAQ)

• What is this product used for?
  It is used for interference testing and assay validation in workflows where rheumatoid factor may affect analytical accuracy, specificity, or signal behavior.
• Why is rheumatoid factor important in assay development?
  Rheumatoid factor can interfere with immunoassay performance by binding assay components or altering detection behavior, which can contribute to inaccurate or misleading results.
• What do the different catalog numbers represent?
  Each catalog number corresponds to a different defined RF titer range, allowing researchers to select the interference level most appropriate for their validation or challenge design.
• What assay platforms is this product relevant to?
  It is especially relevant to ELISA, CLIA, nephelometric, and other immunoassay-based analytical workflows.
• Is this product intended for diagnostic or clinical use?
  No. This product is supplied strictly for in vitro research use only and is not intended for diagnostic, therapeutic, or clinical use.

---

References

• Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, Teslovich NC, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Lee YC, Todd DJ, Bykerk VP, Goodman SM, Pernis AB, Ivashkiv LB, Karlson EW, Nigrovic PA, Filer A, Buckley CD, Lederer JA, Raychaudhuri S, Brenner MB. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017 Feb 1;542(7639):110-114.
• Shi L, Hu F, Xu C, Zhu H, Qie D, Yuan C, Tao Y, Liu H. Plasma exchange successfully treated macrophage activation syndrome in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis with co-existing pneumonia. Int J Rheum Dis. 2018 May;21(5):1142-1145.
• Bartlett DB, Willis LH, Slentz CA, Hoselton A, Kelly L, Huebner JL, Kraus VB, Moss J, Muehlbauer MJ, Spielmann G, Kraus WE, Lord JM, Huffman KM. Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study. Arthritis Res Ther. 2018 Jun 14;20(1):127.
• Fan W, Xu L, Xie L, Yang D, Liu X, Zhang J, Li Y, Yi C. Negative interference by rheumatoid factor of plasma B-type natriuretic peptide in chemiluminescent microparticle immunoassays. PLoS One. 2014 Aug 21;9(8):e105304.
• Taghadosi M, Samimi Z, Assar S, Salahshoor MR, Jalili C. Plasma Leptin Does Not Reflect the Effect of High Body Mass Index on Disease Activity in Rheumatoid Arthritis. Immunol Invest. 2020 Feb;49(1-2):32-45.
• Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015 May;42(5):760-70.
• Hughes-Austin JM, Deane KD, Giles JT, Derber LA, Zerbe GO, Dabelea DM, Sokolove J, Robinson WH, Holers VM, Norris JM. Plasma adiponectin levels are associated with circulating inflammatory cytokines in autoantibody positive first-degree relatives of rheumatoid arthritis patients. PLoS One. 2018 Jun 25;13(6):e0199578.
• Rantapää-Dahlqvist S, Boman K, Tarkowski A, Hallmans G. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis. 2007 Jan;66(1):121-3.
• Lovece S, Stern R, Kagen LJ. Effects of rheumatoid factor, antinuclear antibodies and plasma reagin on the serologic assay for Lyme disease. J Rheumatol. 1991 Dec;18(12):1813-8.
• Twomey JJ, Rossen RD, Lewis VM, Morgan AC, McCormick KJ. Rheumatoid factor positive plasma and humoral cytotoxicity to malignant melanoma. Cancer. 1978 Apr;41(4):1307-12.